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Abstract: Sickle cell anemia (SCA) is a genetic blood disorder that is particularly lethal in
early childhood. Universal newborn screening programs and subsequent early treatment are
known to drastically reduce under-five SCA mortality. However, in resource-limited settings,
cost and infrastructure constraints limit the effectiveness of laboratory-based SCA screening
programs. To address this limitation our laboratory previously developed a low-cost, equipment-free,
point-of-care, paper-based SCA test. Here, we improved the stability and performance of the test by
replacing sodium hydrosulfite (HS), a key reducing agent in the hemoglobin solubility buffer which is
not stable in aqueous solutions, with sodium metabisulfite (MS). The MS formulation of the test was
compared to the HS formulation in a laboratory setting by inexperienced users (n = 3), to determine
visual limit of detection (LOD), readout time, diagnostic accuracy, intra- and inter-observer agreement,
and shelf life. The MS test was found to have a 10% sickle hemoglobin LOD, 21-min readout time,
97.3% sensitivity and 99.5% specificity for SCA, almost perfect intra- and inter-observer agreement,
at least 24 weeks of shelf stability at room temperature, and could be packaged into a self-contained,
distributable test kits comprised of off-the-shelf disposable components and food-grade reagents
with a total cost of only $0.21 (USD).
Keywords: sickle cell anemia; paper-based diagnostics; point-of-care screening
1. Introduction
Sickle cell disease (SCD) refers to a group of common recessively inherited hemoglobin disorders
associated with significant lifelong morbidities and premature mortality. SCD results from the
inheritance of a mutated allele coding for the β-globin subunit of hemoglobin along with another
mutated allele coding for the same or another aberrant form of hemoglobin [1,2]. This mutated
β-globin allele results in the production of sickle hemoglobin (HbS), a form of hemoglobin (Hb) that
polymerizes when deoxygenated, unlike normal adult hemoglobin (HbA). The polymerization of
deoxy-HbS molecules into rigid fibers deforms the red blood cell (RBC) membrane and causes the
characteristic ‘sickled’ shape of affected sickle RBCs. Sickle RBCs are markedly less deformable and
more fragile than normal, healthy RBCs, which causes them to occlude blood vessels, cause chronic
ischemia-reperfusion injury, and lyse frequently, resulting in severe anemia, chronic painful episodes,
and predisposition to infection [3,4].
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When the allele coding for HbS is inherited heterozygously with the allele coding for HbA (i.e.,
genotype HbAS) it causes what is known as sickle cell trait (SCT) where both forms of Hb are produced
and individuals are typically healthy, do not need medical intervention related to HbS, and may
have improved resistance to parasites such as Plasmodium falciparum [3,4]. In Angola, for example,
the HbS allele is present in over 20% of the population, with about 98% of those carriers having the
allele heterozygously [5,6]. However, when the HbS allele is inherited homozygously (i.e., genotype
HbSS), it causes sickle cell anemia (SCA), a condition in which 40–100% of all Hb produced is HbS
and individuals experience some of the most severe symptoms associated with SCD. Homozygous
inheritance of the HbS allele and an allele coding for another non-HbS, aberrant form of Hb results in
other, less common forms of SCD which have varying degrees of clinical severity [7,8]. For the purposes
of this study, we will focus on the differentiation of SCA—the most common form of SCD—from SCT
and normal, healthy individuals (i.e., genotype HbAA).
The mortality rate for SCA is the highest in the first five years of a child’s life, as young children
are prone to acute infections and splenic sequestration crises [9]. Improvements in survival rates
for SCA over the last few decades have been largely due to earlier diagnosis and the initiation of
simple, inexpensive prophylaxis, such as penicillin, to combat opportunistic infections. Almost all
children born in the United States, and many other resource-rich countries, are screened for SCA at
birth as part of universal newborn screening programs that test for diseases and conditions where
early initiation of treatment is crucial for survival and healthy, normal development [10]. However,
due to cost and infrastructure limitations, this type of universal screening is oftentimes not feasible
in the resource-limited settings where the incidence of HbS is highest, such as in sub-Saharan Africa,
where approximately 80% of global individuals with SCA are born [2,4,11]. Nearly all children with
SCA who are diagnosed soon after birth and promptly given treatment survive into adulthood, while
the mortality rates for undiagnosed (and, therefore, untreated) children in sub-Saharan Africa are
estimated to be as high as 50–90% by the age of five years [2,11].
The implementation of wide-spread screening and follow-up care for individuals with SCA has
been predicted to potentially save the lives of up to 10 million children by 2050 in the countries most
affected by the disease (e.g., Nigeria, Angola, Democratic Republic of the Congo, India) [7]. Though
highly successful, most of the pilot screening programs in these settings have used conventional
diagnostic methods such as high-performance liquid chromatography (HPLC) or isoelectric focusing
electrophoresis (IEF) to identify SCA, both of which are relatively high-cost, technically complex,
and dependent on stable infrastructure [12,13]. The requirements and limitations of these conventional
diagnostic methods limit screening to those born in major health centers, and prevent life-saving
screening efforts from reaching more remote, less well-equipped community health outposts and those
born out-of-hospital [13–16].
In order to address these limitations, our research group recently developed a simple, equipment-
and electricity-free, paper-based test capable of differentiating normal (HbAA), SCT (HbAS), and SCA
(HbSS) blood samples [17,18]. The paper-based test was previously shown to be accurate (93% sensitivity,
94% specificity for differentiating SCA), low-cost ($0.07 in material and reagent costs), robust and easy to
use (Angolan health workers were proficient in performing the test after one demonstration), and rapid (less
than 30 min from start to readout) [19]. However, the previously-developed version of the paper-based SCA
screening test required the use of a reducing agent—sodium hydrosulfite (HS)—which quickly becomes
oxidized in aqueous solutions (especially when exposed to oxygen) [18,20]. The relative instability and
volatility of HS made shipping and long-term storage of the previous version of the test impractical [19,20].
Here we describe how replacing HS with a higher concentration of sodium metabisulfite (MS) addressed
the limitations of the previously-developed test without negatively impacting test performance. In this
study we found that, compared to the previous test, the novel MS formulation of the paper-based SCA
screening test has a superior limit of detection (10% vs. 20% HbS of total Hb content), faster readout time
(21 min vs. 30 min), better diagnostic performance (97.3% sensitivity, 99.5% specificity for differentiating
SCA), high intra- and inter-observer agreement (κ = 0.93, κ = 0.87 respectively), longer shelf stability at
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room temperature (at least 24 weeks vs. one week for aqueous storage conditions), and could be packaged
into a self-contained, distributable test kit with a total cost of only $0.21 (USD).
2. Materials and Methods
2.1. Blood Samples
The study protocol was approved by the University of Houston and Baylor College of Medicine
institutional review boards. Venous whole blood samples were obtained with written informed consent
in 4 mL Vacutainer tubes (K2EDTA, BD, Franklin Lakes, NJ, USA) from healthy, normal volunteers and
patients of the Texas Children’s Hematology Centers (Houston, TX, USA). Blood samples were stored
at 4 ◦C and used within two months following collection. The sickle hemoglobin (HbS) content of
blood samples from individuals with sickle cell anemia (SCA) was quantified with high-performance
liquid chromatography (HPLC; Primus Ultra Variant, Trinity Biotech, Wicklow, Ireland). Healthy
volunteers were assumed to have 0% HbS. Hematocrit (Hct) and hemoglobin concentration ([Hb]) were
measured with an automated hematology analyzer (Medonic, Boule Medical AB, Spånga, Sweden),
and ABO-RhD blood type was determined using blood type test kits (EldonCard, Eldon Biologicals,
Gentofte, Denmark).
Artificially-reconstituted blood samples with specific Hct (22%—a physiological Hct for SCA) and
HbS concentrations (0, 10, 20, 40, and 80% HbS) were made by combining type-matched blood samples
from normal (HbAA) and SCA (HbSS) individuals. Sample Hct was adjusted via centrifugation at
500× g for 10 min (Beckman Microfuge 22R, Beckman Coulter, Brea, CA, USA) and reconstitution of
red blood cell (RBC) sediment in autologous plasma. The type-matched and Hct-matched HbAA and
HbSS blood samples were then combined at various ratios according to the following equation:
%HbS =
([Hb]HbSS)(VHbSS)(%HbSHbSS)
([Hb]HbSS)(VHbSS) + ([Hb]HbAA)(VHbAA)
, (1)
where V is the volume, subscripted HbSS refers to samples from patients with SCA, and subscripted
HbAA refers to samples from healthy, normal volunteers.
For this study, venous blood samples were collected as described above. For the self-contained
SCA screening test kit, capillary blood can be collected via finger or heel prick. Capillary and
venous blood have both been shown to produce comparable diagnostic results for the assay [18–20].
Additionally, the HS version of the paper-based SCA screening test has been previously shown to be
robust against variations in Hct and associated variations in [Hb] within the physiological range [18,19].
Physiological concentrations of fetal hemoglobin (HbF) amongst infants, adults, and hydroxyurea
patients were also shown to not impact test performance [18,19].
Blood samples used to perform the study of test kit stability were replaced with new
samples—with the same Hcts and HbS concentrations—after 20 days of storage at 4 ◦C in order to
counteract any potential effects due to storage-based RBC and/or Hb deterioration (i.e., storage lesion).
2.2. Hemoglobin Solubility Buffers
The hemoglobin solubility buffers compared in this study each consisted of three components: saponin
(Sigma-Aldrich, St. Louis, MO, USA), a reducing agent, and a concentrated phosphate buffer [17–20].
Potassium phosphate buffer at 2.49 M was made by dissolving solid 1.24 M (169 g/L) monobasic and 1.25 M
(217 g/L) dibasic potassium phosphate (Sigma-Aldrich, St. Louis, MO, USA) in deionized water. Saponin
(4 g/L) was added to irreversibly lyse RBCs by creating holes in the lipid bilayer through sequestration of
cholesterol, thereby releasing hemoglobin into the buffer [19]. The saponin used in this study was obtained
from Quillaja bark (sapogenin content not less than 10%) and contained impurities which made the powder
hygroscopic [21]. The reducing agent—either HS (30 g/L; 3% w/v; Sigma-Aldrich, St. Louis, MO, USA)
or MS (100, 150 or 200 g/L; 10, 15, 20% w/v; Sigma-Aldrich, St. Louis, MO, USA)—then converts the
released Hb into deoxy-Hb, which is either soluble (e.g., deoxy-HbA, deoxy-HbF, deoxy-HbC) or insoluble
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(deoxy-HbS) in the phosphate buffer [17–20]. Additionally, buffer consisting of food-grade MS (Duda
Energy LLC, Decatur, AL, USA) and food-grade saponin (Desert King, San Diego, CA, USA) was made
using the same concentrations as above.
The stability of the MS and HS solubility buffers was compared under two storage conditions: ‘wet’
and ‘dry’. Dry refers to the saponin and MS or HS being stored in dry powdered form and mixed with
concentrated phosphate buffer on the day of the experiment, while wet refers to dry reagents premixed
with concentrated phosphate buffer and stored until the day of the experiment. Individual sets of reagents
were stored within heat-sealed polyethylene-lined 2 mm thick foil pouches (Xin Jiu Technology, Taoyuan,
Taiwan) to prevent exposure of reducing agents and hygroscopic compounds in saponin to oxygen and
humidity outside of the packaging. The reagents were stored and tested at room temperature (18–26 ◦C,
30–50% relative humidity). The buffers were stored between one and 166 days before use. Results from
tests performed using stored buffers were compared against those for reagents prepared on the same day
of the experiment from dry powdered ingredients stored in their original containers.
2.3. Design and Operation of the Paper-Based Test
The design and operation of the paper-based SCA screening test have previously been described
in detail [17–20]. Briefly, 20 µL of whole blood is collected and mixed with Hb solubility buffer by
inversion, the blood and buffer mixture is allowed to incubate at room temperature for 10 min, 20 µL
of blood is then dropped onto chromatography paper (Whatman Chr 1, Sigma-Aldrich, St. Louis, MO,
USA) and allowed to dry (Figure 1b). Insoluble deoxy-HbS polymers, if present, become entangled in
the paper substrate and form a dark red spot in the center of the stain, while soluble forms of Hb wick
laterally through the paper pores and produce a more diffuse pink ring (Figure 1c).
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metabisulfite) via manual agitation; and (iii) after 10 min, a drop (~20 µL) of the mixture is deposited 
on the chromatography paper using the reagent dropper and allowed to dry for up to 25 min before 
being evaluated visually. (c) Representative bloodstains produced by the metabisulfite (top) and 
hydrosulfite (bottom) versions of the paper-based test for samples with various sickle hemoglobin 
(HbS) concentrations. The limit of detection (LOD) for each version is indicated by a dashed line. 
Typical HbS concentration ranges for adults and children older than six months of age with different 
genotypes (normal—HbAA; SCT—HbAS; SCA—HbSS) are marked below the stains. 
Figure 1. Overview of the distributable paper- i nostic test kit. (a) Ph tograph of the
sickle c ll kit with all components neces ary t t test: (i) patterned chromatography aper;
(ii) reagent tube containing r ts; (iii) reagent dropper; (iv) blood dropper; and (v) foil pouch.
(b) Schematic illustration showing the steps required to perform the paper-based test: (i) ~20 µL of
whole blood is collected via finger-stick using the blood dropper and deposited in the reagent tube;
(ii) the blood is mixed with a preset volume of buffer (containing either sodium hydrosulfite or sodium
metabisulfite) via manual agitation; and (iii) after 10 min, a drop (~20 µL) of the mixture is deposited
on the chromatography paper using the reagent dropper and allowed to dry for up to 25 min before
being evaluated visually. (c) Representative bloodstains produced by the metabisulfite (top) and
hydrosulfite (bottom) versions of the paper-based test for samples with various sickle hemoglobin
(HbS) concentrations. The limit of detection (LOD) for each version is indicated by a dashed line.
Typical HbS concentration ranges for adults and children older than six months of age with different
genotypes (normal—HbAA; SCT—HbAS; SCA—HbSS) are marked below the stains.
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2.4. Blood Stain Pattern Interpretation
Blood stain patterns were interpreted visually by eye and/or digitized using a portable scanner
(CanoScan LiDE110, Canon USA, Lake Success, NY, USA) and quantified using a custom image
analysis algorithm implemented in MATLAB (The MathWorks, Natick, MA, USA). Inexperienced
users (n = 3) with little to no experience performing and interpreting the paper-based test were
provided with a set of representative images of blood stain patterns resulting from both the MS and
HS versions of the test performed using normal, SCT, and SCA blood samples (using Hb solubility
buffer prepared on the same day of the experiment from dry powdered ingredients stored in their
original containers). The previously described ‘S-index’—defined as the quotient of the mean red color
intensity of pixels in the center spot area of the blood stain and the mean red color intensity of pixels in
the ring area of the blood stain (red color intensity = 255 − B, where B is the blue channel of the RGB
values for the digitized image)—was used to quantify the differences between blood stain patterns
produced by different formulations of the test [18].
2.5. Test Performance and Statistical Analysis
Test performance metrics were calculated as: Sensitivity = TP/(TP + FN); specificity = TN/(FP
+ TN); positive predictive value (PPV) = TP/(TP + FP); negative predictive value (NPV) = TN/(TN +
FN); and accuracy = (TP + TN)/(TP + FP + TN + FN), where TP = true positive, FP = false positive,
TN = true negative, and FN = false negative. Fleiss’ kappa statistic was used to assess intra- and
inter-operator agreement for visual scoring of blood stains [22,23]. Mean, standard deviation, p-values,
and confusion matrices were calculated using built-in functions in MATLAB 2014b (The MathWorks,
Natick, MA, USA).
3. Results
We hypothesized that we could improve the stability and performance of our
previously-developed paper-based screening test for SCA by replacing a key component of
the Hb solubility buffer, sodium hydrosulfite (HS), with sodium metabisulfite (MS), a chemically
stable food additive. The concentration of MS used to replace HS was determined by comparing
the previously described S-index—defined as the quotient of the red color intensities of the center
area (proportional to the amount of HbS) and the ring area (proportional to other forms of Hb)
of the blood stain—for buffer formulations with 10, 15, and 20% MS (w/v) to the S-index for
the previously-developed buffer formulation with 3% HS (w/v) for a set of samples with HbS
concentrations from 0 to 40% HbS [18]. 15% MS (w/v) was chosen as the final formulation for the
Hb solubility buffer because it produced the greatest difference in the S-Index between 0 and 20%
HbS, and the most gradual change in S-Index over the range of 20–40% HbS. The Hb solubility buffer
containing 15% MS (w/v) was used to perform all experiments described in this study.
3.1. Limit of Detection
The limit of detection (LOD) for this test is defined as the lowest percentage of HbS (out of the total
amount of Hb in a sample) that will produce a blood stain on paper which is visually distinguishable
from characteristic blood stains for samples without HbS (0%). The previously developed HS test is
capable of identifying SCA in adults and children older than six months of age and has a reported
LOD of ~15% HbS [19]. To determine the LOD of the MS version of the test, inexperienced users (n = 3)
were asked to visually score a set of images of blood stains in paper (n = 370) produced by the MS
formulation of the test (370 stains × 3 users = 1110 total scores) as either HbS-negative (HbS = 0%) or
HbS-positive (HbS > 0%). The inexperienced users correctly scored 820 of the 888 blood stain images
with ≥10% HbS (92.3%) as having some HbS and 220 of the 222 blood stain images with <10% HbS
(99.1%) as having no HbS. These results suggest that, when evaluated visually by an inexperienced
user, the LOD of the MS formulation of the paper-based SCA screening test was ~10% HbS. This LOD
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was confirmed to produce the greatest AUC (area under the curve) on an ROC (receiver operating
characteristic) curve.
3.2. Test Readout Time
After the mixture of blood and Hb solubility buffer is deposited on chromatography paper,
it takes approximately 25 min for the blood stain to become completely dry. However, accurate visual
diagnoses can be made from blood stain patterns before they are completely dry. Inexperienced users
(n = 3) were asked to visually score blood stains for unknown samples every minute for 25 min as
the stains dried following deposition of the mixture onto paper. Samples with 0% HbS (normal) were
correctly scored by all three users after 7 min of drying time, samples with HbS levels characteristic
of SCT (10–40% HbS) were correctly scored by all users after 11 min, and samples with HbS levels
characteristic of SCA (>40% HbS) could be scored correctly after 1 min. These results suggest that the
paper-based SCA screening test can be performed and interpreted within 21 min (10 min preparation
and incubation +11 min drying before readout).
3.3. Test Performance Metrics
To determine the performance of the MS version of the test, inexperienced users (n = 3) were
asked to visually score a set of images of blood stains on paper (n = 185) produced by the MS version
of the test as either normal (HbAA; characteristic HbS = 0%), SCT (HbAS; characteristic HbS = 10–40%)
or SCA (HbSS; characteristic HbS > 40%) by comparing them to a set of representative blood stain
images from each category. Figure 2 shows the aggregate confusion matrices of the visual diagnoses
made by the three inexperienced users with both the MS and HS versions of the paper-based test.
Using the MS formulation inexperienced users could visually distinguish between blood samples with
no HbS and blood samples with ≥10% HbS (i.e., HbAA vs. HbAS and HbSS) with 92.8% sensitivity,
100% specificity, 100% positive predictive value (PPV), 77.6% negative predictive value (NPV) and
94.2% overall diagnostic accuracy (Figure 2a). Users could also distinguish between blood samples
with ≥80% HbS (characteristic of SCA) from blood samples with <80% HbS (characteristic of normal
and SCT) (i.e., HbSS vs. HbAA and HbAS) with 97.3% sensitivity, 99.5% specificity, 98.2% PPV, 99.3%
NPV, and 99.1% overall diagnostic accuracy (Figure 2a).
When the same three inexperienced users were asked to score blood stains on paper (n = 143)
produced by the previously-developed HS formulation of the test, they could visually distinguish
between blood samples with no HbS and blood samples with ≥10% HbS (i.e., HbAA vs. HbAS
and HbSS) with 61.2% sensitivity, 100% specificity, 100% PPV, 49.2% NPV, and 71.8% overall
diagnostic accuracy (Figure 2b). Users could also distinguish between blood samples with ≥80% HbS
(characteristic of SCA) from blood samples with <80% HbS (characteristic of normal and SCT) (i.e.,
HbSS vs. HbAA and HbAS) with 76.9% sensitivity, 100% specificity, 100% PPV, 95.1% NPV, and 95.8%
overall diagnostic accuracy (Figure 2b).
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whether MS was stored under dry or wet conditions. The difference between blood stain patterns for 
Figure 2. Diagnostic accuracy of the paper-based SCA screening test kit. (a) Aggregate confusion matrix
for screening of blood samples (n = 185) with characteristic HbS concentrations via visual interpretation
(inexperienced users; n = 3) of the blood stains produced on paper by the metabisulfite (MS) formulation
of the test (185 samples× 3 users = 555 total scores). (b) Aggregate confusion matrix for the screening of
blood samples (n = 143) with characteristic HbS concentrations via visual interpretation (inexperienced
users; n = 3) of the blood stains produced on paper by the hydrosulfite (HS) formulation of the test
(143 samples × 3 users = 429 total scores). Rows correspond to characteristic genotypes (based on HbS
concentration measured using conventional high-performance liquid chromatography—HPLC) and
columns correspond to predicted genotypes (diagnosed by the paper-based test). Shaded cells contain
the numbers of correct diagnoses.
3.4. Intra- and Inter-Observer Agreement
The Fleiss’ kappa statistical measure (κ) for assessing intra-observer agreement of the scoring of
blood stains on paper (n = 370) produced by the S version of the test was κ = 0.93 ± 0.04 (individual
scores: 0.88, 0.93, and 0.97), which suggests that there was almost perfect self-consistency for each of
the three inexperienced test users. The Fleiss’ kappa statistical measure for assessing inter-observer
agree ent for the S version of the test was κ = 0.87, which suggests that there was al ost perfect
agreement between the three inexperienced test users. hen the same three inexperienced users were
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asked to score blood stains on paper (n = 286) produced by the previously-developed HS formulation
of the test, κ = 0.85 ± 0.09 (individual scores: 0.72, 0.88, and 0.94) for intra-observer agreement and
κ = 0.75 for inter-observer agreement. These results suggest that there is a very high level of intra-
and inter-observer agreement for visual diagnosis of SCT and SCA using the HS version of the test,
but that both intra- and inter-observer agreement are better for the MS version of the test.
3.5. Test Kit Stability
Figure 3 shows the stability of the reagents comprising the Hb solubility buffer for the MS and
HS formulations of the paper-based test when stored under dry (MS powder stored separately from
aqueous buffer components) or wet (MS powder mixed with aqueous buffer components before
storage) conditions over the course of 24 weeks. Reagents were considered stable as long as the
difference in the S-index—defined as quotient of the red color intensities of the center area and ring
area of the blood stain—between samples with 0% HbS and samples with HbS concentrations greater
than, or equal, to the LOD of tests performed using fresh reagents (i.e., ≥10% HbS for MS and ≥20%
HbS for HS) remained statistically significant (p < 0.05).
The MS formulation maintained stability over the course of all 24 weeks studied regardless of
whether MS was stored under dry or wet conditions. The difference between blood stain patterns for
samples with 0% HbS and≥10% HbS was still visually obvious and statistically significant (p < 0.05) at
the end of the 24-week study period (Figure 3). When stored under dry conditions the HS formulation
remained 100% stable until day 36 (~5 weeks) of the study period, after which it lost all activity—i.e.,
the difference in blood stain patterns for samples with 0% HbS and ≥20% HbS was not visually
obvious or statistically significant (p > 0.05). When stored under wet conditions the HS formulation
remained 100% stable until day 6 (~1 week) of the study period, after which it lost all activity (Figure 3).
These results suggest that, regardless of whether MS is stored in dry or wet form, the MS version of the
test has a shelf life which is (at the least) ~5 times as long as the shelf life for a dry HS version of the test
and ~24 times as long as the shelf life for a wet HS version of the test. Additional testing showed that,
when stored under wet conditions, the MS formulation remained 100% stable for (at least) one week
when stored at 62 ◦C (an upper bound on hot temperatures reached in storage in desert climates [24]).
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Figure 3. Representative images of blood stains demonstrating the reagent stability of the metabisulfite
(MS) and hydrosulfite (HS) formulations of the paper-based SCA screening test under wet and dry
storage conditions. (left) Blood stain images for samples with 0% HbS (control) produced by the MS
and HS versions of the test using freshly prepared reagents. (right) Blood stain images for samples
with 20% HbS (limit of detection of HS version of test) produced by the MS and HS versions of the
test using reagents stored und r wet (MS powder mixed with aqueous buffer components before
storage) r dry (MS powder stored separately from aque us buff r components) conditions. The limit
of stability (LOS)—i.e., the maximum amount of ti e reagents can be stored before the iff rence in
patt rn b tween sampl s with 0% HbS and samples with HbS concen rations greater than, or equal
o, the limit of detection of tests p rformed u ing f esh reagents becomes statis ically insignificant—is
dicated by a dashed line.
3.6. istributable Test Kit Cost
self-contained, distributable kit containing all reagents and materials necessary to perform
the paper-based SCA screening test as described above was assembled using the follo ing
co ercially-available, off-the-shelf components: blood dropper (Microsafe 20 µL, Safe-Tec, Ivyland,
PA, USA), reagent tube (0.5 mL microcentrifuge tube, Sigma-Aldrich, St. Louis, MO, USA), reagent
dropper (Disposable Graduated Transfer Pipet, VWR, Radnor, PA, USA), chromatography paper
(Whatman Chr 1, Sigma-Aldrich, St. Louis, MO, USA), and a foil polyethylene-lined pouch (Xin Jiu
Technology, Taoyuan, Taiwan) (Figure 1a). The key reagents used in this test kit were food-grade:
sodium metabisulfite (Duda Energy, Decatur, AL, USA) and saponin (Desert King, San Diego, CA,
USA). Table 1 shows a cost breakdown for the reagents and materials comprising the self-contained,
distributable paper-based SCA screening test kit. The total cost of all materials, reagents and packaging
necessary to perform the paper-based SCA screening test using this kit was $0.21 (USD).
Table 1. Detailed cost breakdown of the paper-based SCA screening test kit components.
Test Component Cost Per Test (USD)
Foil pouch $0.02
Reagent dropper $0.05
Blood dropper $0.08
Chromatography paper $0.01
Reagent tube $0.03
Food grade reagents $0.02
Total $0.21
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4. Discussion
Universal screening for SCA using conventional, laboratory-based methods (e.g., IEF, HPLC) is
currently unfeasible in many resource-limited settings because of the prohibitively high cost and lack
of access to the technical infrastructure required to support such testing. The advent of a simple, stable,
equipment-free, visually-interpreted and inexpensive screening test for SCA could greatly improve
the survival rate of the hundreds of thousands born with the disease each year, by enabling an earlier
initiation of simple and effective prophylactic care. The point-of-care screening technology described in
this study has the potential to significantly decrease the cost and technical complexity of implementing
universal screening programs in resource-limited regions where SCA has the highest incidence [7].
Recently, multiple research groups have developed screening tests for sickle cell disease intended
for use in resource-limited settings [25–28]. Some of the most promising emerging technologies include
an antibody-based lateral flow assay that can detect HbS, HbA, and HbC and an aqueous multiphase
system used to separate dense sickle RBCs from healthy RBC populations with lower density [25–27,29].
However, none of the current or developing tests adequately address all of the unique design
requirements necessary to create a test which can be distributed, stored, performed, and interpreted
in resource-limited settings. For example, antibody-based tests are notoriously prone to stability
and reproducibility issues when taken outside the laboratory, since antibodies generally denature
above 37 ◦C (mammalian body temperature) and are rarely specific (nonspecific antibodies may bind
unintended antigens to produce a false positive signal) [26]. However, the antibody-based SCD assay
is simple to use, has shown >98% sensitivity and specificity in a laboratory setting for identifying HbSS
blood, can accurately determine the presence of HbC (100% sensitivity and specificity) and has the
potential to be very effective at identifying other non-HbS hemoglobin variants [25,26]. As a result,
the antibody-based SCD assay is most appropriate for situations where high genotypic resolution (i.e.,
the ability to specifically identify different SCD genotypes) is needed, but may be constrained from
a cost and long-term stability perspective. The density-based test, on the other hand, is highly sensitive
to changes in reagent properties (e.g., change in density due to evaporation) and is not equipment-
and electricity-free (i.e., requires a car-battery powered centrifuge) [29]. The complexity of the density
based test, and its sensitivity to comorbidities and other factors that influence RBC density, such as high
amounts of HbF in newborns, resulted in lower sensitivity (86%) and specificity (60%) for identifying
HbSS blood in resource-limited settings in Zambia [29]. Furthermore, the density-based test has not
been able to distinguish HbAS from HbAA [27,29]. As such, none of the technologies currently on the
market or in public development fully address the unmet need for a truly simple, stable, and low-cost
SCA screening test.
Our research laboratory has previously attempted to meet this need by developing and validating
a paper-based SCA screening test capable of sensitive and specific differentiation of SCA from SCT
and normal individuals in adults and children older than six months of age [17,19]. However, the Hb
solubility buffer on which the previously-developed test is based utilized a reducing agent—sodium
hydrosulfite (HS)—which is expensive to ship and difficult to store due to its combustibility as a solid
(Hazmat Class 4.2—spontaneously combustible) and fast oxidation in aqueous solutions (t1/2 < 1 day at
25 ◦C) [30]. Here we presented the development and characterization of an alternative formulation of
the Hb solubility buffer that eliminates the need for HS via substitution of an optimized concentration
of sodium metabisulfite (MS)—a common preservative used in the food, textile, and photography
industries. MS is approximately half the price of HS when purchased commercially, is not a regulated
substance (i.e., does not need to be shipped as hazardous goods), and is stable for up to a year as
a solid at room temperature and at least ~6 months in solution with exposure to oxygen [30].
The MS formulation of the paper-based SCA screening test described here successfully addresses
many of the technical and logistical problems of the conventional approaches described above as well
as the limitations of the previously developed HS formulation. Firstly, the use of MS instead of HS
increased the shelf-life of the aqueous Hb solubility buffer by up to ~24× (Figure 3), thus allowing
for the packaging of a distributable kit containing premade buffer with a reasonably long shelf-life.
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The MS formulation maintained stability over the course of a 24-week period regardless of storage
under dry or wet conditions—i.e., the difference in the blood stain pattern between samples with 0%
HbS and ≥10% (the LOD for MS tests performed using fresh reagents) HbS was still visually obvious
and statistically significant (p < 0.05) at the end of the study period (Figure 3). In contrast, the HS
formulation only remained stable for ~5 weeks under dry conditions and ~1 week under wet conditions
(Figure 3). Additional experiments showed that the MS formulation of the test remained stable for
at least one week when stored under wet conditions at 62 ◦C (an upper bound on hot temperatures
reached in desert climates on Earth [24]). The improved storage capability of the MS-based assay will
be crucial for the expansion of SCA screening programs in regions without established supply chains
and clinical facilities.
Secondly, in addition to improving the stability of the paper-based SCA test, the substitution of
MS for HS improved the LOD of the assay by two-fold, allowing for the detection of as little as 10%
HbS in a blood sample, compared to 15% HbS with HS. Inexperienced users visually differentiated
SCA from normal or SCT samples with 97.3% sensitivity, 99.5% specificity, and almost perfect
agreement between scorers (Figure 2a). In comparison, when using the HS test, users were only
able to visually differentiate SCA with 76.9% sensitivity and 100% specificity (Figure 2b). Given the
higher concentration of metabisulfite used to achieve blood stain color intensities similar to the HS
test, this improvement in LOD could be partially due to the increase in Hb solubility buffer osmolality,
which causes more HbS to precipitate out of the solution and form a darker stain center spot on
the paper [18]. It has previously been shown that HS deoxygenates HbS rapidly, resulting in the
formation of amorphous precipitates of short, randomly-oriented Hb fibers, while MS has been
shown to deoxygenate Hb more gradually, resulting in the formation of long, organized Hb polymers
characteristic of SCA [31,32]. These comparatively larger deoxy-HbS aggregates formed using MS are
more likely to become entangled within the chromatography paper pores—causing a higher fraction
of total deoxy-HbS to be retained in the area of the initial drop (center spot)—compared to the smaller,
more irregular aggregates formed using HS, which are more likely to be wicked laterally through the
paper pores toward the edge of the stain (peripheral ring). Therefore, an alternate explanation for the
improvement in LOD could be that the larger fraction of total deoxy-HbS retained in the area of the
initial drop, as a result of using MS compared to HS, produces center spots which are both darker
(higher absolute amount of deoxy-HbS in the center spot) and more well-defined (lower fraction of
deoxy-HbS in peripheral ring) [33]. This improvement in signal detection is an important development
for screening young children, who produce less HbS (due to increased HbF (fetal Hb) production) than
is observed in typical adult Hb profiles.
Additionally, the MS formulation of the test can be performed and interpreted more rapidly than
the HS formulation. Inexperienced users made accurate visual diagnoses from blood stain patterns
within 11 min of deposition onto chromatography paper (i.e., before the blood stains on the paper
were fully dry) which corresponds to 21 min from the start of the test. This is an improvement over the
reported readout time of 30 min for the HS test. The more rapid availability of test results could permit
immediate clinical intervention at the point-of-care and could potentially enable counseling of families
with SCA newborns before discharge. The ability to deliver results during the first visit to a health
clinic is vital because in regions which lack established communication infrastructure, re-contact and
follow-up rates for affected newborns have been reported to be as low as 50% [5].
Finally, using MS allowed for the design of a self-contained, low-cost test kit comprised of
easily-accessible, food-grade reagents (not an option for HS) and off-the-shelf disposable plastic
components with a total cost of $0.21 (USD) (Table 1). The test kit consists of a blood dropper, reagent
dropper, reagent tube, food grade reagents, chromatography paper and a foil pouch (Figure 1a),
with >66% of the total cost being accounted for by the disposable plastic droppers. Switching from HS
to MS also decreased the amortized cost of the test significantly (primarily due to shipping restrictions
on HS). The transportation, storage, and material cost savings of this MS-based test, as well as the
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wide availability of food-grade MS, make the SCA screening test a tangible reality in even the most
resource-limited settings.
The MS formulation of the paper-based test described in this study has two important limitations.
First, when visually interpreted, the test cannot differentiate between SCA and other heterozygous
forms of SCD (e.g., HbSC). This is because the blood stain pattern produced in paper is determined by
the concentration of HbS in the blood sample being tested and is unaffected by the relative proportions
of other soluble forms of Hb making up the rest of the sample. As such, the paper-based test would
have the highest clinical utility in regions with low SCD genotypic variation (e.g., Angola where the
majority of SCD cases are SCA [5]) and lowest utility in regions where other forms of SCD are present
(e.g., Burkina Faso and Central West Africa where HbSC is prevalent [34]). Importantly however,
we have previously shown that automated image analysis of scanned blood stain patterns can be used
to differentiate HbAS from HbSC (sensitivity of 100%, specificity of 59%) despite human scorers being
unable to differentiate the patterns by eye [19]. Second, while the LOD of the MS formulation of the
test has been improved to 10% HbS, this LOD may still be insufficient for detecting SCT or SCA in
newborns less than six months of age. This is because at birth the cord blood of SCT newborns contains
9.5 ± 4.2% HbA and 6.5 ± 2.8% HbS, and the blood of newborns with SCA contains 10.2 ± 3.9% HbS,
meaning that newborns with HbS concentrations near the low end of this physiological range may
produce false negative results [35,36]. To address this limitation we have previously developed and
validated a separate HS-based test which employs a disposable filter to further improve the LOD of
the test, however, this version of the test is currently incapable of differentiating SCT from SCA [20].
In summary, we have improved and characterized the performance of our previously-developed
paper-based test for rapid, low-cost, and equipment-free diagnosis of SCA in resource-limited settings.
We have demonstrated that the test, compared to the previous version, had a superior limit of
detection, faster readout time, better diagnostic performance, longer shelf stability at room temperature,
and could be packaged into a self-contained, distributable test kit with a total cost of only $0.21 (USD).
A point-of-care test with these qualities represents a significant step towards enabling population-wide
screening in resource-limited settings, which, in combination with prompt initiation of prophylactic
treatment, could have a transformative impact on the health and well-being of the hundreds of
thousands of individuals with SCA born in developing countries each year.
Supplementary Materials: The following are available online at www.mdpi.com/2079-6374/7/3/39/s1:
Figure S1. Time-lapse of Test from Kit to Readout.
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